… Read the rest
An updated policy statement issued this week by the American Academy of Pediatrics (AAP) calls for federally rescheduling cannabis in order to better facilitate clinical trial research and to promote its pharmaceutical development.
The new position statement resolves: “The AAP strongly supports research and development of pharmaceutical cannabinoids and supports a review of policies promoting research on the medical use of these compounds. The AAP recommends changing marijuana from a Drug Enforcement Administration Schedule I (controlled substance) to a Schedule II drug to facilitate this (clinical) research.”
By definition, Schedule I controlled substances are defined as possessing no “accepted medical use.” Clinical protocols involving cannabis are strictly controlled and require authorization from various federal agencies, including DEA, FDA, and the National Institute on Drug Abuse (NIDA) – the latter of which is designated under federal law as the sole provider of cannabis and/or organic cannabinoids for research purposes.